telehealth.helpFind my match

Home WikiTelehealth History & timeline

GLP-1 drug shortage (2022-2025)

From WikiTelehealth, the telehealth.help reference · Last updated

The GLP-1 drug shortage was a period from 2022 to 2025 when the FDA listed semaglutide and tirzepatide injections on its national drug shortage list because demand was higher than supply. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved on February 21, 2025.

GLP-1 drug shortage (2022-2025)
DrugsSemaglutide and tirzepatide injections
Listed2022 (tirzepatide on December 15, 2022)
Tirzepatide resolvedOctober 2, 2024 (confirmed December 19, 2024)
Semaglutide resolvedFebruary 21, 2025
AgencyU.S. Food and Drug Administration
Last grace period endedMay 22, 2025 (503B, semaglutide)

Background

The FDA keeps a public drug shortage list. A drug goes on the list when the agency finds that national supply cannot meet current or expected demand. Semaglutide injections (sold as Ozempic and Wegovy) were placed on the list in 2022. Tirzepatide injections (sold as Mounjaro and later Zepbound) were added on December 15, 2022.

Demand for these medicines rose quickly as more people used them for weight loss and type 2 diabetes. During the shortage, many patients reported trouble filling prescriptions for some doses at local pharmacies.

Role of compounding pharmacies

Federal law normally limits how often pharmacies may make copies of an FDA-approved drug. When a drug is on the shortage list, those limits are relaxed. During the GLP-1 shortage, state-licensed 503A pharmacies and 503B outsourcing facilities prepared compounded semaglutide and compounded tirzepatide. Compounded drugs are made for an individual prescription and are not FDA-approved products.

Resolution of the shortage

The FDA first marked the tirzepatide shortage as resolved on October 2, 2024. The agency then agreed to look at the decision again and confirmed it in a new order on December 19, 2024. For tirzepatide, the FDA set the end of its grace period at February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities.

On February 21, 2025, the FDA found that the semaglutide shortage was also resolved. It confirmed with the maker that supply could meet current and expected national demand. For semaglutide, the grace period ended on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities.

Compounding groups challenged both decisions in federal court in Texas. The court denied their requests to pause the decisions on March 5, 2025 for tirzepatide and on April 24, 2025 for semaglutide.

After the shortage

Once a drug leaves the shortage list, pharmacies may no longer make products that are essentially copies of the approved drug. The FDA has stated that 503A pharmacies may still prepare a compounded version when a prescriber decides that a change is needed for an individual patient. Readers who want to see how brand-name and compounded programs compare today can use our comparison of compounded and brand-name GLP-1s.

Timeline

  1. 2022Semaglutide injection products are placed on the FDA drug shortage list. (FDA statement on GLP-1 supply)
  2. December 15, 2022Tirzepatide injection products are added to the FDA drug shortage list. (FDA declaratory order, December 19, 2024)
  3. October 2, 2024The FDA marks the tirzepatide shortage as resolved. (FDA statement on GLP-1 supply)
  4. December 19, 2024After a second review, the FDA confirms the tirzepatide shortage is resolved. (FDA declaratory order, December 19, 2024)
  5. February 18, 2025Grace period for 503A pharmacies compounding tirzepatide ends (later tied to the March 5, 2025 court ruling). (FDA statement on GLP-1 supply)
  6. February 21, 2025The FDA declares the semaglutide shortage resolved. (FDA statement on GLP-1 supply)
  7. March 19, 2025Grace period for 503B outsourcing facilities compounding tirzepatide ends. (FDA statement on GLP-1 supply)
  8. April 22, 2025Grace period for 503A pharmacies compounding semaglutide ends (confirmed after the April 24, 2025 court ruling). (FDA statement on GLP-1 supply)
  9. May 22, 2025Grace period for 503B outsourcing facilities compounding semaglutide ends. (FDA statement on GLP-1 supply)

Compare compounded and brand-name programs

See also

References

  1. FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize". fda.gov
  2. FDA, Declaratory order: resolution of shortages of tirzepatide injection products (December 19, 2024). fda.gov
  3. FDA, Resolution of shortages of semaglutide injection products (February 21, 2025). fda.gov

Last updated . Category: History & timeline. Browse all 38 WikiTelehealth entries.